BGHL (EUR): NAV(s)
September 10, 2024 01:30 ET
|
BOUSSARD AND GAVAUDAN HOLDING LIMITED (EUR)
BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would like to announce the following...
BGHL (GBP): NAV(s)
September 10, 2024 01:30 ET
|
BOUSSARD AND GAVAUDAN HOLDING LIMITED (GBP)
BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would like to announce the following...
OSE Immunotherapeutics annonce le lancement international d’Artemia, l’étude de Phase 3 d’enregistrement du vaccin thérapeutique Tedopi® en deuxième ligne de traitement du cancer du poumon non à petites cellules
September 10, 2024 01:30 ET
|
OSE Immunotherapeutics
OSE Immunotherapeutics annonce le lancement international d’Artemia, l’étude de Phase 3 d’enregistrement du vaccin thérapeutique Tedopi® en deuxième ligne de traitement du cancer du poumon non à...
OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer
September 10, 2024 01:30 ET
|
OSE Immunotherapeutics
OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer Trial begins in the United States, Canada,...
Planisware identifié comme leader dans le Magic Quadrant™ 2024 de Gartner® en Gestion de Projet Adaptative et Reporting
September 09, 2024 15:45 ET
|
Planisware
Planisware identifié comme leader dans le Magic Quadrant™ 2024 de Gartner® en Gestion de Projet Adaptative et Reporting Paris, France, 9 septembre 2024 – Planisware, un leader de l’édition de...
Planisware recognized as a Leader in 2024 Gartner® Magic Quadrant™ for Adaptive Project Management & Reporting report
September 09, 2024 15:45 ET
|
Planisware
Planisware recognized as a Leader in 2024 Gartner® Magic Quadrant™ for Adaptive Project Management & Reporting report Paris, France, September 9, 2024 – Planisware, a leading B2B provider of...
Next-Generation Cancer Diagnostics Market to Reach USD 47.2 Billion By 2033, Driven by Technological Advancements and Personalized Medicine Trends
September 09, 2024 13:34 ET
|
Dimension Market Research
New York, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Overview The Global Next Generation Cancer Diagnostics Market size is expected to reach USD 19.1 billion by 2024. It is further anticipated to reach a...
Sinus Dilation Devices Market Size Is Expected to Reach USD 8.3 Bn by 2033, at 10.0% CAGR: Dimension Market Research
September 09, 2024 13:26 ET
|
Dimension Market Research
New York, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Overview The Global Sinus Dilation Devices Market size is expected to reach a market value of USD 3.5 billion in 2024 and it is further anticipated to...
Bubble Tea Market is expected to reach a revenue of USD 2.8 Bn by 2033, at 8.4% CAGR: Dimension Market Research
September 09, 2024 13:25 ET
|
Dimension Market Research
New York, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Overview The Global Bubble Tea Market size is expected to reach USD 2.8 billion by 2024 and is further anticipated to reach USD 5.8 billion by 2033...
Monoclonal Antibodies Market to Reach USD 804.7 Billion By 2033, Driven by Technological Advancements and Personalized Medicine Trends
September 09, 2024 13:19 ET
|
Dimension Market Research
New York, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Overview The Global Monoclonal Antibodies Market size is expected to reach USD 279.8 billion by 2024 and it is further anticipated to reach a market...